3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Ovarian Neoplasms
7
Small Cell Lung Carcinoma
6
Fallopian Tube Neoplasms
4
Lung Neoplasms
3
Sarcoma, Ewing
2
Neuroblastoma
2
Neoplasm Metastasis
2
Central Nervous System Neoplasms
2
Wilms Tumor
1
Uterine Cervical Neoplasms
1
SCLC
1
Rhabdoid Tumor
1
Pleuropulmonary blastoma
1
Peritoneal Neoplasms
1
Pancreatic Neoplasms
1
Osteosarcoma
1
Neoplasms
1
Ganglioneuroblastoma
1
Extensive Stage Small Cell Lung Cancer (ES-SCLC)
1
Endometrial Neoplasms
1
Choroid Plexus Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Neuroendocrine
1
Interventions
X-Rays
4
Phantoms, Imaging
4
Nuclear Medicine Department, Hospital
4
Magnetic Resonance Spectroscopy
4
Specimen Handling
3
Biopsy
3
ulixertinib
2
tipifarnib
2
selpercatinib
2
ivosidenib
2
erdafitinib
2
ensartinib
2
tazemetostat
1
talazoparib
1
palbociclib
1
olaparib
1
larotrectinib
1
irinotecan sucrosofate
1
Vemurafenib
1
Temozolomide
1
Pharmacogenomic Variants
1
Liquid Biopsy
1
LY3023414
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Neuroectodermal Tumors, Primitive, Peripheral
×
Topotecan
×
30 days
×
Clear all
No trials found.